JP7258860B2 - 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ - Google Patents

抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ Download PDF

Info

Publication number
JP7258860B2
JP7258860B2 JP2020515656A JP2020515656A JP7258860B2 JP 7258860 B2 JP7258860 B2 JP 7258860B2 JP 2020515656 A JP2020515656 A JP 2020515656A JP 2020515656 A JP2020515656 A JP 2020515656A JP 7258860 B2 JP7258860 B2 JP 7258860B2
Authority
JP
Japan
Prior art keywords
proadm
sample
level
fragments
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533603A5 (https=
JP2020533603A (ja
JPWO2019053117A5 (https=
Inventor
ダライアス ウィルソン
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59887051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7258860(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020533603A publication Critical patent/JP2020533603A/ja
Publication of JP2020533603A5 publication Critical patent/JP2020533603A5/ja
Publication of JPWO2019053117A5 publication Critical patent/JPWO2019053117A5/ja
Priority to JP2023061326A priority Critical patent/JP2023095851A/ja
Application granted granted Critical
Publication of JP7258860B2 publication Critical patent/JP7258860B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2020515656A 2017-09-13 2018-09-13 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ Active JP7258860B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061326A JP2023095851A (ja) 2017-09-13 2023-04-05 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190913 2017-09-13
EP17190913.8 2017-09-13
PCT/EP2018/074724 WO2019053117A1 (en) 2017-09-13 2018-09-13 PCT AND PRO-ADM USED AS CONTROL MARKERS IN ANTIBIOTIC TREATMENT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061326A Division JP2023095851A (ja) 2017-09-13 2023-04-05 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ

Publications (4)

Publication Number Publication Date
JP2020533603A JP2020533603A (ja) 2020-11-19
JP2020533603A5 JP2020533603A5 (https=) 2022-05-26
JPWO2019053117A5 JPWO2019053117A5 (https=) 2022-05-26
JP7258860B2 true JP7258860B2 (ja) 2023-04-17

Family

ID=59887051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515656A Active JP7258860B2 (ja) 2017-09-13 2018-09-13 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
JP2023061326A Pending JP2023095851A (ja) 2017-09-13 2023-04-05 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061326A Pending JP2023095851A (ja) 2017-09-13 2023-04-05 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ

Country Status (10)

Country Link
US (1) US20200264199A1 (https=)
EP (2) EP3682241B2 (https=)
JP (2) JP7258860B2 (https=)
CN (1) CN111094981B (https=)
BR (1) BR112020004150A2 (https=)
CA (1) CA3075442C (https=)
DK (1) DK3682241T4 (https=)
ES (1) ES2913298T5 (https=)
WO (1) WO2019053117A1 (https=)
ZA (1) ZA202001108B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094981B (zh) 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
RU2724186C1 (ru) * 2020-01-23 2020-06-22 Наталья Борисовна Гусева Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139475A1 (en) 2009-06-05 2010-12-09 B.R.A.H.M.S Gmbh Detection of bacterial infections in subjects suffering from dyspnea

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
CN103123359B (zh) * 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5989965B2 (ja) * 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
EP2545379B1 (en) * 2010-03-08 2015-09-30 B.R.A.H.M.S GmbH Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
EP2976646B1 (en) * 2013-03-20 2020-08-19 sphingotec GmbH Adrenomedullin to guide therapy of blood pressure decline
CN111094981B (zh) 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139475A1 (en) 2009-06-05 2010-12-09 B.R.A.H.M.S Gmbh Detection of bacterial infections in subjects suffering from dyspnea

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANGELETTI, S. et al.，Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin(MR-proADM) in bacterial infections，APMIS; Acta Pathologica, Microbiologica, et Immunologica Scandinavica，2015年，Vol.123, No.9，pp.740-748
ANGELETTI, S. et al.，Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis，Clinical Chemistry and Laboratory Medicine，2012年10月16日，Vol.51, No.5，pp.1059-1067
SCHUETZ, P. et al.，Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia，Current Opinion in infectious Diseases，2013年04月，Vol.26, No.2，pp.159-167
SHUAIBI, M. A. et al.，Pro-adrenomedullin as a Novel Biomarker for Predicting Infections and Response to Antimicrobials in Febrile Patients With Hematologic Malignancies，Clinical Infectious Diseases，2013年，Vol.56, No.7，pp.943-950
Silvia Angeletti et al.，Diagnostic and prognostic role of procalcitonin(PCT) and MR-pro-Adrenomedullin(MR-proADM) in bacterial infections，APMIS; Acta Pathologica, Microbiologica, et Immunologica Scandinavica，2015年，123(9)，740-748

Also Published As

Publication number Publication date
CN111094981B (zh) 2024-04-16
ZA202001108B (en) 2022-08-31
CA3075442C (en) 2024-04-02
EP3682241A1 (en) 2020-07-22
EP4027145A1 (en) 2022-07-13
RU2020111718A3 (https=) 2022-02-01
WO2019053117A1 (en) 2019-03-21
RU2020111718A (ru) 2021-10-13
EP3682241B2 (en) 2025-09-10
US20200264199A1 (en) 2020-08-20
DK3682241T4 (da) 2025-10-06
JP2020533603A (ja) 2020-11-19
DK3682241T3 (da) 2022-05-16
ES2913298T3 (es) 2022-06-01
CN111094981A (zh) 2020-05-01
CA3075442A1 (en) 2019-03-21
EP3682241B1 (en) 2022-03-30
WO2019053117A8 (en) 2021-01-21
BR112020004150A2 (pt) 2020-09-08
ES2913298T5 (en) 2026-01-02
JP2023095851A (ja) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7579353B2 (ja) 重症急性呼吸器症候群（ｓａｒｓ）における疾患進行を予後診断するためのプロアドレノメデュリン
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
JP2024091650A (ja) 多発外傷患者の外傷関連合併症の予後診断のためのｐｒｏ－ａｄｍ
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
US20240393352A1 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
RU2820944C2 (ru) Проадм для прогнозирования риска состояния, требующего госпитализации, у пациентов с симптомами инфекционного заболевания
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258860

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250